BioSpace News Archive

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products reported business and financial results for the fiscal second quarter ended March 31, 2023.

Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.

Mass General Brigham and Dana-Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development the Jawaher Boston Medical District, a state-of-the-art health care system designed to deliver world-class, patient-centered care through innovation, technology, and sustainability.

Precision BioSciences, Inc. announced that its late-breaking abstract presenting preclinical in vivo gene editing data for its PBGENE-DMD program, being developed for the potential treatment of Duchenne muscular dystrophy, is available through the American Society of Gene & Cell Therapy 26th Annual Meeting.

RELIEF THERAPEUTICS Holding SA announced that it has filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission.

Illumina announced that Institutional Shareholder Services, a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein.